|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results demonstrate a STAT3/NF-κB/IDO pathway in breast cancer-derived MDSCs, which provides insight into understanding immunosuppressive mechanisms of MDSCs in breast cancer.
|
25063873 |
2014 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer.
|
29037255 |
2017 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expression of PD L1 was noted in 30%, PD L2 in 18%, IDO1 in 13%, and CTLA4 in 14% of 333 nonviral malignancies including endometrial, ovarian, lung, and breast cancers.
|
28697066 |
2017 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
SIGNIFICANCE: These findings show in a model of HER2<sup>+</sup> breast cancer that necrosis secondary to impaired efferocytosis activates IDO1 to drive immunosuppression and tumor progression.
|
30413412 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study aimed to assess the expression of HLA-G and IDO activity in breast cancer and normal ASCs and to see whether ASC is capable of modulating both tumor cells and immune system cells in vitro.
|
29076586 |
2018 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this experimental study, we assessed the expressions of indolamine 2, 3-dioxygenase (<i>IDO1</i>), <i>IDO2</i> and human leukocyte antigen-G5 (<i>HLA-G5</i>) in ASCs isolated from breast cancer patients with different stages as well as normal individuals, using quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR).
|
28367424 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
The association of ER overexpression with epigenetic downregulation of IDO1 appears to be a particular feature of breast cancer as <i>IDO1</i> was not suppressed by <i>IDO1</i> promoter hypermethylation in the presence of high ER expression in cervical or endometrial cancer.
|
28344890 |
2017 |
|
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We present data suggesting that inhibiting COX-2 activity in vivo regulates IDO expression within the tumor microenvironment; this is further corroborated in the MDA-MB-231 human breast cancer cell line.
|
16888001 |
2006 |
|
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Data suggested that the expression of IDO1 on Epcam-positive breast cancer 4T1 and MCF-7 decreased MuS110/MT110 antitumor efficacy by the suppression of T cells activation in vitro.
|
29128855 |
2018 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using 4T1 tumor cell-engrafted mouse model, we also detected the expression of indoleamine 2,3-dioxygenase (IDO) in tumor tissues after DOX treatment and further explored whether the specific small molecule IDO1 inhibitor NLG919 combined with DOX, can exhibit better therapeutic effects on breast cancer.
|
31281723 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
We use needle biopsy breast cancer tissues prior to neoadjuvant chemotherapy(NCT) staining for CD33, Foxp3 and IDO by immunohistochemistry to evaluate whether they were correlated with subsequent treatment responses in breast cancer.
|
29621426 |
2018 |
|
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In silico analysis of IDO 1 gene expression in breast cancer showed its association with several genes related to immune response and apoptosis.
|
24687552 |
2014 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
The current study provides preclinical evidence that AMD3465 treatment in combination with IDO1 inhibition may be a promising therapeutic regimen for refractory metastasized breast cancers.
|
31388305 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers.
|
28264810 |
2017 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we treated male and female 3xTg-AD and wild-type mice with the novel IDO inhibitor DWG-1036 (80 mg/kg) or vehicle (distilled water) from 2 to 6 months of age and then tested them in a battery of behavioral tests that measured spatial learning and memory (Barnes maze), working memory (trace fear conditioning), motor coordination and learning (rotarod), anxiety (elevated plus maze), and depression (tail suspension test).
|
31607909 |
2019 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated whether indoleamine 2,3-dioxygenase1 (IDO1)-mediated tryptophan (TRP) metabolism plays a critical role in depression occurring as a side effect of IFN-α therapy.
|
27436416 |
2016 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
Body image dissatisfaction is strongly associated with inflammation and mucosa-derived IDO activation independently from depression, pregnancy, BMI and age.
|
27427239 |
2018 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
Indolamine 2, 3 dioxygenase (IDO) pathway is considered to be an important pathway in pro-inflammatory cytokine associated stress-induced depression.
|
28911850 |
2017 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this work, we assessed the relationship between single-nucleotide polymorphisms (SNPs) of KAT1, KAT2 and IDO1 gene encoding, and the risk of depression development.
|
29777939 |
2018 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
The kynurenine pathway (KP) and its rate-limiting tryptophan degrading enzyme, indolamine 2,3 dioxygenase (IDO), have been implicated in the pathogenesis of depression.
|
29787958 |
2018 |
|
Mental Depression
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, the present data show for the first time that resolution of inflammation-induced depression is an active process requiring T lymphocytes acting via an IL-10-dependent pathway to decrease Ido1 expression in the brain.
|
30054585 |
2018 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results reveal an IDO1-mediated regulatory mechanism underlying the comorbidity of pain and depression and suggest a new strategy for the concurrent treatment of both conditions via modulation of brain IDO1 activity.
|
22751107 |
2012 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
We hypothesized that GM-CSF could exert antidepressant effects through IDO downregulation in a model for acute inflammation-induced depression.
|
31153376 |
2019 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hence, this study was envisaged to evaluate the dose dependent inhibition of indoleamine 2,3-dioxygenase (IDO) enzyme employing quercetin (screened employing in vitro method) with levetiracetam for combined management of epilepsy and comorbid depression.
|
28065794 |
2017 |
|
Mental Depression
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IDO expression is driven by inflammatory cytokines, and has been suggested as the link between inflammation and a serotonergic deficit in depression.
|
22683764 |
2012 |